Sunday, September 29, 2019 11:57:20 AM
___________________________________________________________________________________
Pain Patent (from georgejjl)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151086364
Investor 2014 links to a list of patents with Alexandre Vamvakides dating back to 2008 gives an idea:
https://patents.justia.com/inventor/alexandre-vamvakides
Patent update re: AV1066.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149346961
AVXL patent on AI to treat Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169367
IP.....good article on Intellectual Property in the BioPharma sector
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150118360
Greenspam3 links to new patent applications for visceral and neuropathic pain and also regulation of blood pressure:
https://patentscope.wipo.int/search/en/detail.jsf?docId=US243292967&recNum=1&office&queryString=FP%3A%28anavex%29&prevFilter&sortOption=Pub+Date+Desc&maxRec=38&fbclid=IwAR0iQoR01ea7s1UHVBUfMZG9_2CFKNXSiBIZHsMoQ7R7qQBMIbF_crtkokE
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019108653&tab=PCTBIBLIO&office&prevFilter&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&recNum=2&maxRec=38&fbclid=IwAR1R-6LmOI1qaWSmh1gixjbLF6qLMAuhqT2mS-DT173ea-5uiJId_DNz6iA
Beginning of discussion for above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149304398
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931 (the “Patent”). The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer’s disease (AD), type 2 diabetes and insulin resistance. (posted by georgejjl)
https://www.anavex.com/anavex-awarded-new-u-s-patent/
United States Patent Application January 24, 2019
NEURODEVELOPMENTAL DISORDER THERAPY
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148757220
Patent filing released 04/25/19: Anavex 2-73 for the Treatment of Cardiac Dysfunction
(from TTTav66)
https://patentscope.wipo.int/search/de/detail.jsf?docId=US241444653
Discussion here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148457849
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148470928
Patent - ANAVEX2-73 in a method of treatment for neurodevelopmental disorders:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148472474
AV1066 for pain an approved patent which is "ready for issue" as of 12/28/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145909839
Patent for specific crystaline forms of 2-73 provides extended IP protection:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420021
Patent for Insomnia: (EN) A2-73 AS A THERAPEUIC FOR INSOMNIA, ANXIETY, AND AGITATION
Abstract:
(EN)A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg. (from basparks79)
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=173B4DDABFF25B0C26F75F5B8E98D703.wapp2nA?docId=WO2018022848&recNum=1&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&tab=PCT+Biblio
More on the patent for Insomnia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144833903
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144834373
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144842204
Anavex, Cognision, and Ariana are doing ground breaking research in Alzheimer's disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113
December 20, 2018 Anavex & Cognision U.S. Patent Application, intermittent dosage :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145735301
more info on Cognision in the partners post
The following posts relate to the above patent:
Tool suite used in the above patent (thanks Nidan7500):
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
https://www.advancedbrainmonitoring.com/
Summary of Checci patent Application:
https://investorshub.advfn.com/boards/read_msg.aspx?
ERP patent app with related organizations:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147781853
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147668300
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147844189
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271
Additional info in Anavex partners post linked at the bottom of the primary post.
Recent AVXL News
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans • GlobeNewswire Inc. • 01/24/2024 12:30:00 PM
- Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 01/16/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 01:00:34 AM
- Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM